Department of Medicine 3 – Rheumatology and Immunology

Lysosome-targeting amplifiers of reactive oxygen species as anticancer prodrugs (2017) Daum S, Reshetnikov V, Sisa M, Dumych T, Lootsik MD, Bilyy R, Bila E, et al. Journal article T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients (2016) Mummert C, Hofmann C, Hueckelhoven AG, Bergmann S, Mueller-Schmucker SM, Harrer EG, Dörrie J, et al. Journal article Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells (2016) Magorivska I, Munoz Becerra L, Janko C, Dumych T, Rech J, Schett G, Nimmerjahn F, et al. Journal article A patient with ankylosing spondylitis Ein patient mit spondylitis ankylosans (2016) Waltering I, Rech J, Rose O, Derendorf H Journal article Type 2 Innate Lymphoid Cells - Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis (2016) Weber S, Wohlfahrt T, Rauber S, Luber M, Englbrecht M, Dees C, Beyer C, et al. Conference contribution Sensitivity and Specificity of Autoantibodies Against CD74 in Early Axial Spondyloarthritis (2016) Witte T, Riechers E, Baerlecken NT, Baraliakos X, Bakhsh KAM, Aries P, Bannert B, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial (2016) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution THE INVOLVEMENT OF THE LONG NONCODING H19X IN TGF beta SIGNALING AND ITS PROFIBROTIC EFFECTS IN SYSTEMIC SCLEROSIS AND OTHER FIBROTIC DISEASES (2016) Pachera E, Assassi S, Salazar G, Frank-Bertoncelj M, Dobrota R, Brock M, Kurreeman F, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1 (2016) Kavanaugh A, Mease P, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY (2016) Distler O, Maurer B, Vettori S, Blumhardt S, Frey D, Distler A, Beyer C, Distler J Conference contribution